Pharmaceutical compositions comprising poh derivatives

Abstract

The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene). The route of administration may vary, and can include, inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

1 - 23 . (canceled) 
     
     
         24 . The pharmaceutical composition comprising the POH derivative octadeca-9, 12-dienoic acid 4-isopropenyl-cylcohex-1-enylmethyl ester (linoleoyl ester of POH) having the chemical formula: 
       
         
           
           
               
               
           
         
       
     
     
         25 . The pharmaceutical composition of  claim 24 , wherein the pharmaceutical composition may be administered before, during, or after radiation. 
     
     
         26 . The pharmaceutical composition of  claim 24 , wherein the pharmaceutical composition is administered by topical application. 
     
     
         27 . The pharmaceutical composition comprising the POH derivative hexadecanoic acid 4-isopropenyl-cylcohex-1-enylmethyl ester (palmitoyl ester of POH) having the chemical formula: 
       
         
           
           
               
               
           
         
       
     
     
         28 . The pharmaceutical composition of  claim 27 , wherein the pharmaceutical composition may be administered before, during, or after radiation. 
     
     
         29 . The pharmaceutical composition of  claim 27 , wherein the pharmaceutical composition is administered by topical application. 
     
     
         30 . A method for treating a disease in a mammal, comprising the step of delivering to the mammal a therapeutically effective amount of the pharmaceutical composition octadeca-9, 12-dienoic acid 4-isopropenyl-cylcohex-1-enylmethyl ester (linoleoyl ester of POH), wherein the therapeutically effective amount of octadeca-9, 12-dienoic acid 4-isopropenyl-cylcohex-1-enylmethyl ester (linoleoyl ester of POH) is administered before, during or after radiation treatment. 
     
     
         31 . The method of  claim 30 , which further comprises delivering to the mammal a chemotherapeutic agent. 
     
     
         32 . The method of  claim 30 , wherein the pharmaceutical composition is administered by topical application. 
     
     
         33 . The method of  claim 30 , wherein the disease is cancer. 
     
     
         34 . The method of  claim 33 , wherein the cancer include, but is not limited to, lung cancer, ear, nose and throat cancer, leukemia, colon cancer, melanoma, pancreatic cancer, mammary cancer, prostate cancer, breast cancer, hematopoietic cancer, ovarian cancer, basal cell carcinoma, biliary tract cancer; bladder cancer; bone cancer; breast cancer; cervical cancer; choriocarcinoma; colon and rectum cancer; connective tissue cancer; cancer of the digestive system; endometrial cancer; esophageal cancer; eye cancer; cancer of the head and neck; gastric cancer; intra-epithelial neoplasm; kidney cancer; larynx cancer; leukemia including acute myeloid leukemia, acute lymphoid leukemia, chronic myeloid leukemia, chronic lymphoid leukemia; liver cancer; lymphoma including Hodgkin's and Non-Hodgkin's lymphoma; myeloma; fibroma, neuroblastoma; oral cavity cancer (e.g., lip, tongue, mouth, and pharynx); ovarian cancer; pancreatic cancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; rectal cancer; renal cancer; cancer of the respiratory system; sarcoma; skin cancer; stomach cancer; testicular cancer; thyroid cancer; uterine cancer; cancer of the urinary system, as well as other carcinomas and sarcomas. 
     
     
         35 . A method for treating a disease in a mammal, comprising the step of delivering to the mammal a therapeutically effective amount of the pharmaceutical composition hexadecanoic acid 4-isopropenyl-cylcohex-1-enylmethyl ester (palmitoyl ester of POH) is administered before, during or after radiation treatment. 
     
     
         36 . The method of  claim 35 , which further comprises delivering to the mammal a chemotherapeutic agent. 
     
     
         37 . he method of  claim 35 , wherein the pharmaceutical composition is administered by topical application. 
     
     
         38 . The method of  claim 35 , wherein the disease is cancer. 
     
     
         39 . The method of  claim 38 , wherein the cancer include, but is not limited to, lung cancer, ear, nose and throat cancer, leukemia, colon cancer, melanoma, pancreatic cancer, mammary cancer, prostate cancer, breast cancer, hematopoietic cancer, ovarian cancer, basal cell carcinoma, biliary tract cancer; bladder cancer; bone cancer; breast cancer; cervical cancer; choriocarcinoma; colon and rectum cancer; connective tissue cancer; cancer of the digestive system; endometrial cancer; esophageal cancer; eye cancer; cancer of the head and neck; gastric cancer; intra-epithelial neoplasm; kidney cancer; larynx cancer; leukemia including acute myeloid leukemia, acute lymphoid leukemia, chronic myeloid leukemia, chronic lymphoid leukemia; liver cancer; lymphoma including Hodgkin's and Non-Hodgkin's lymphoma; myeloma; fibroma, neuroblastoma; oral cavity cancer (e.g., lip, tongue, mouth, and pharynx); ovarian cancer; pancreatic cancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; rectal cancer; renal cancer; cancer of the respiratory system; sarcoma; skin cancer; stomach cancer; testicular cancer; thyroid cancer; uterine cancer; cancer of the urinary system, as well as other carcinomas and sarcomas.